KCT0008113尚未招募未知
Multi-center, Randomized, Subject & Evaluator-blind, Matched pairs, Active-controlled design Pivotal study to Evaluate the Efficacy and Safety of Injection with SkinPlus-HYAL Implant Lidocaine as Compared to RESTYLANE Lidocaine in temporary Correction of Nasolabial folds
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1. Men and women over 19 years of age
- •2. Subject who want to temporarily improve both nasolabial folds have a Wrinkle Severity Rating Scale (WSRS) of 3 or 4 points (both do not need to be the same score)
- •3. Subject who has agreed to discontinue all dermatological treatments or treatments (filler, botulinum toxin, laser treatment, chemical exfoliation, cosmetic surgery, etc.) including the improvement of wrinkles in the face area during this clinical trial
- •4. Subject who can understand and follow the instructions and participate in the entire clinical trial period
- •5. Subject who voluntarily decides to participate in this clinical trial and agrees in writing to the informed consent form
排除标准
- •1. Subject who administered anti-thrombotic drugs (excluding low-dose aspirin (100 mg, up to 300 mg/day) from 2 weeks before to 2 weeks after application of Investigational devices for clinical trials, and vitamin E and NSAID drugs from 1 week before application
- •2. Subject who has a medical history of bleeding at a past or present time
- •3. Subject who has received CaHA (calcium hydroxyapatite) or PLLA (poly L-lactide) filler treatment at the Investigational device application area for clinical trials within one year from the date of screening
- •4. Subject who have used local applicants (steroids, retinoids: medicines only, not cosmetics) on the face within 4 weeks of the screening date or who are scheduled to use them during the clinical trial period (However, steroid ointment can be used for a short period of time within 14 consecutive days)
- •5. Subject who have used immunosuppressants, chemotherapy agents, or systemic corticosteroids within 12 weeks of screening date
- •6. Subject who has received treatment for wrinkle improvement or acne scars within 24 weeks from the date of screening
- •7. Subject who has undergone an epidermis, skin regeneration, or plastic surgery (including botulinum toxin injection) on the face within 24 weeks from the date of screening
- •8. Subject who insert permanent skin extension prosthesis such as soft form or silicone into the face
- •9. Subject who has a skin disease or wound infection in the face area that affects this clinical trial
- •10. Subject with a medical history of autoimmune diseases
- •11. Subject who overreact to sodium hyaluronate
- •12. Subject with streptococcal disease
- •13. Subject who has experienced anaphylaxis or severe allergic symptoms
- •14. Subject who has a medical history of hypertrophic scarring, hyperpigmentation, or keloid
- •15. Subject with hypersensitivity to lidocaine or other amide-based local anesthetic
- •16. Subject with blood clotting disorder
- •17. Subject who has had or currently has a mental illness that has significant clinical disabilities in the cardiovascular system, digestive system, respiratory system, endocrine system, and central nervous system
- •18. Subject who participates in another clinical trial within 30 days from the date of screening and administers/applied Investigational devices for clinical trials
- •19. Among female subjects who are likely to be pregnant, those who do not agree to use contraception* by medically permitted methods up to 48 weeks after the application of Investigational devices in this clinical trial
- •*Medically acceptable contraceptive methods: condoms, oral contraceptives that last at least three months, injections or implantable contraceptives, and intrauterine contraceptives installed, etc
- •20. Pregnant or lactating women
- •21.Subject who uses steroids for the purpose of treatment (immunity disease, musculoskeletal disease, etc.) within 4 weeks of participation in the test or plans to use them during the test period
- •22. Subject who use functional cosmetics that improve wrinkles within 4 weeks of participation in the test or who plan to use them during the test period
- •23. In addition to the above, Principal Investigator or Investigator has clinically significant findings that are medically deemed inappropriate for this test
研究者
相似试验
招募中
不适用
Pivotal study to Evaluate the Efficacy and Safety of Injection with HyaFilia ME:DAM Prime PLUS as Compared to RESTYLANE Lidocaine in temporary Correction of Nasolabial foldsDiseases of the skin and subcutaneous tissueKCT0006956Asan Medical Center100
已完成
不适用
A clinical study of the safety and effectiveness of ionized atelocollagen based adhesion barrier(Collabarrier®) for adhesion prevention in spine surgeryDiseases of the musculoskeletal system and connective tissueKCT0007858Dalim Tissen68
已完成
不适用
medical device pivotal clinical study to assess the anti-adhesive effect and safety of ABT13107 compared to Hyalobarrier applied to postoperative intrauterineDiseases of the skin and subcutaneous tissueKCT0002393Medytox192
尚未招募
不适用
A clinical study to evaluate the adhesion prevention and safety of HYCOGUARDgel® versus Guardix-SP ® in patients after operation for spinal surgeryKCT0005799MEDIJ96
已完成
3 期
Safety and efficacy assessment of Rituximab (Zydus) in comparison with Rituximab (Roche/Genentech) in Patients with Diffuse Large B Cell Lymphoma (DLBCL)CTRI/2018/07/014885Cadila Healthcare Ltd153